Post-Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System.

HOME
>
論文・技術情報
>
Post-Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System.

アブストラクト
ジャーナル名	International journal of dermatology
Pubmed追加日	2025/9/24
投稿者	Tran, Tung S; Le, Duc V; Jacobs, Jena C; Nguyen, Trang M; Wetter, David A; Nguyen, Giang H
組織名	Hanoi Medical University, Hanoi, Vietnam.;National Hospital of Dermatology and Venereology, Hanoi, Vietnam.;Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.;Bassett Medical Center, Cooperstown, New York, USA.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/40990361/